Evaluation of 68Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1

[1]  M. Pavel,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors , 2017, Neuroendocrinology.

[2]  A. Colao,et al.  Role of 68Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1) , 2016, Endocrine.

[3]  P. Herscovitch,et al.  Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. , 2015, Journal of the American College of Surgeons.

[4]  Rakesh Kumar,et al.  Accuracy of 68Ga DOTANOC PET/CT Imaging in Patients With Multiple Endocrine Neoplasia Syndromes , 2015, Clinical nuclear medicine.

[5]  J. Mortensen,et al.  64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients , 2015, The Journal of Nuclear Medicine.

[6]  K. Delman,et al.  Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach , 2015, Annals of Surgical Oncology.

[7]  J. Schulz,et al.  A phantom-based method to standardize dose-calibrators for new &bgr;+-emitters , 2015, Nuclear medicine communications.

[8]  E. D. de Vries,et al.  EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. , 2015, Gastrointestinal endoscopy.

[9]  U. Knigge,et al.  PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. , 2014, Future oncology.

[10]  I. Steffen,et al.  Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT , 2014, Radiology and oncology.

[11]  E. Hindié,et al.  Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors , 2014, The Journal of Nuclear Medicine.

[12]  G. Valk,et al.  Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis. , 2014, Endocrine-related cancer.

[13]  B. Ge,et al.  Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis , 2014, Acta radiologica.

[14]  M. Lassmann,et al.  Dosimetry of [⁶⁸Ga]-labeled compounds. , 2013, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[15]  J. Bilezikian,et al.  Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). , 2012, The Journal of clinical endocrinology and metabolism.

[16]  W. Brenner,et al.  Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia , 2012, Annals of Nuclear Medicine.

[17]  A. Tabarin,et al.  Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[18]  V. Ambrosini,et al.  68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  H. Amthauer,et al.  68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol , 2011, The Journal of Nuclear Medicine.

[20]  T. de Baère,et al.  Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. , 2011, The Journal of clinical endocrinology and metabolism.

[21]  R. Buchert,et al.  Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  E. Krenning,et al.  Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. , 2010, Gastroenterology.

[23]  A. Tabarin,et al.  Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients , 2010, World Journal of Surgery.

[24]  M. Cuggia,et al.  Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors , 2009, Journal of Nuclear Medicine.

[25]  M. Rothmund,et al.  Age‐related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers , 2007, Clinical endocrinology.

[26]  A. Runz,et al.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[28]  Judit Erchegyi,et al.  Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.

[29]  F. Gleeson,et al.  Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[30]  B. Långström,et al.  Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity. , 2004, Bioconjugate chemistry.

[31]  J. Bertherat,et al.  Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. , 2003, The Journal of clinical endocrinology and metabolism.

[32]  A. Engel,et al.  SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumours , 2003, Clinical endocrinology.

[33]  Uwe Haberkorn,et al.  Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[34]  L. Mortelmans,et al.  111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging , 2003, European journal of nuclear medicine and molecular imaging.

[35]  Y Wang,et al.  Positional cloning of the gene for multiple endocrine neoplasia-type 1. , 1997, Science.